DeepMed Research

Ohsu Knight Cancer Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ohsu.edu/knight-cancer-institute

Clinical Trials

Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma

Interventions: Drug: Ibrutinib
Biological: Obinutuzumab

First Posted Date: 2016-04-13

Last Posted Date: 2022-01-05

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 10

Registration Number: NCT02736617

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Phase 1

Active, not recruiting

Conditions: Recurrent Prostate Carcinoma
Metastatic Prostate Carcinoma
Castration-Resistant Prostate Carcinoma
Stage IV Prostate Cancer AJCC v7

Interventions: Drug: Cabazitaxel
Drug: Enzalutamide
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Prednisone

First Posted Date: 2015-08-13

Last Posted Date: 2025-03-14

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 37

Registration Number: NCT02522715

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸
Portland VA Medical Center, Portland, Oregon, United States

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Stage IV Non-Small Cell Lung Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Pharmacological Study
Drug: Selumetinib

First Posted Date: 2015-07-21

Last Posted Date: 2023-03-21

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 23

Registration Number: NCT02503358

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

Phase 1

Completed

Conditions: Recurrent Plasma Cell Myeloma
Plasma Cell Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Drug: Ixazomib Citrate
Drug: Melphalan
Drug: Methotrexate
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Quality-of-Life Assessment
Drug: Tacrolimus

First Posted Date: 2015-07-21

Last Posted Date: 2020-11-23

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 11

Registration Number: NCT02504359

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer

Not Applicable

Terminated

Conditions: Health Status Unknown
Prostate Carcinoma

Interventions: Procedure: 3 Tesla Magnetic Resonance Imaging
Radiation: Gadodiamide
Procedure: Multiparametric Magnetic Resonance Imaging
Procedure: Transrectal Biopsy
Procedure: Ultrasound-Guided Prostate Biopsy

First Posted Date: 2015-07-17

Last Posted Date: 2019-04-03

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT02501759

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Phase 2

Completed

Conditions: Pancreatic Adenocarcinoma
Resectable Pancreatic Carcinoma

Interventions: Drug: Fluorouracil
Drug: Gemcitabine
Radiation: Image Guided Radiation Therapy
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Drug: Nab-paclitaxel
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2015-04-28

Last Posted Date: 2023-09-06

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 20

Registration Number: NCT02427841

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma

Not Applicable

Completed

Conditions: Glioblastoma

Interventions: Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Drug: Ferumoxytol
Drug: Gadoteridol
Procedure: Magnetic Resonance Imaging

First Posted Date: 2015-02-09

Last Posted Date: 2022-03-17

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 29

Registration Number: NCT02359097

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

CATCH-UP Intervention in Increasing Cancer Screening and Prevention Care in Uninsured Patients at Community Health Centers

Completed

Conditions: Health Status Unknown
Malignant Neoplasm
Breast Carcinoma
Human Papillomavirus Infection
Colorectal Carcinoma
Cervical Carcinoma

Interventions: Other: Informational Intervention

First Posted Date: 2015-02-04

Last Posted Date: 2020-08-19

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 45

Registration Number: NCT02355262

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Phase 2

Active, not recruiting

Conditions: Recurrent Prostate Carcinoma
Hormone-Resistant Prostate Cancer
Stage IV Prostate Adenocarcinoma Cancer AJCC v8
Castration-Resistant Prostate Carcinoma
PSA Progression

Interventions: Drug: Enzalutamide
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab

First Posted Date: 2014-12-09

Last Posted Date: 2025-03-13

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 58

Registration Number: NCT02312557

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Contrast Enhanced MRI of the Prostate

Completed

Conditions: Prostatic Neoplasms

First Posted Date: 2014-09-19

Last Posted Date: 2020-09-17

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 14

Registration Number: NCT02245282

Locations: 🇺🇸
Advanced Imaging Research Center, OHSU, Portland, Oregon, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy